CYSTO-CONRAY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CYSTO-CONRAY (CYSTO-CONRAY).
Radiopaque contrast agent: contains iodine which attenuates X-rays, allowing visualization of vessels and organs. Distributes in extracellular fluid and is excreted by glomerular filtration.
| Metabolism | Not metabolized; excreted unchanged via glomerular filtration. |
| Excretion | Primarily renal excretion via glomerular filtration. Approximately 95% of the administered dose is excreted unchanged in urine within 24 hours. Fecal excretion is negligible (<1%). |
| Half-life | Terminal elimination half-life ranges from 1.5 to 2.5 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged. Clinical context: rapid renal clearance limits systemic accumulation; prolonged half-life in renal impairment may necessitate dose adjustment. |
| Protein binding | Negligible protein binding (approximately 5%, primarily to albumin). |
| Volume of Distribution | Apparent volume of distribution (Vd) is approximately 0.2-0.3 L/kg, indicating distribution primarily in the extracellular fluid compartment. Clinical meaning: low Vd reflects limited tissue penetration; the agent remains largely in the vascular and interstitial spaces. |
| Bioavailability | Intravenous: 100% (complete bioavailability). Intra-arterial: 100%. Not administered orally; oral bioavailability is negligible due to poor gastrointestinal absorption and intended use as a parenteral contrast agent. |
| Onset of Action | Intravenous administration: immediate (within minutes); intra-arterial: immediate. Intravenous urography: enhancement of urinary tract occurs within 5-10 minutes. Cystography: direct instillation yields immediate opacification. |
| Duration of Action | Intravenous urography: diagnostic enhancement persists for 30-60 minutes post-injection, depending on renal function. Direct cystography: effect lasts until drainage or micturition. Clinical note: effect duration is short; imaging timing is critical. |
Intravenous or intra-arterial administration, typical adult dose: 25-50 mL (of 282 mg I/mL solution) for cerebral angiography; 40-80 mL for aortography; 10-30 mL for selective visceral angiography; 20-50 mL for coronary arteriography; 50-100 mL for peripheral arteriography; 300-500 mL for drip-infusion pyelography (diluted 1:1 with saline or dextrose solution).
| Dosage form | Solution |
| Renal impairment | Contraindicated in anuria or significant renal impairment (eGFR <30 mL/min/1.73m²). No dose adjustment sufficient; use alternative diagnostic modality if possible. For moderate impairment (eGFR 30-59), ensure adequate hydration and consider lowest possible dose; monitor renal function post-procedure. |
| Liver impairment | No specific Child-Pugh based dose adjustments. Caution in severe hepatic impairment due to potential for contrast-induced nephrotoxicity; use lowest diagnostic dose and monitor renal function. |
| Pediatric use | Weight-based dosing: 0.5-1.0 mL/kg (of 282 mg I/mL solution) for intravenous urography; up to 2-3 mL/kg for total body opacification studies. Adjust for immature renal function; ensure adequate hydration. Maximum single dose: 5 mL/kg. |
| Geriatric use | Use lowest effective dose (often less than 50 mL total) due to age-related renal function decline; ensure adequate hydration before and after procedure; monitor renal function post-procedure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CYSTO-CONRAY (CYSTO-CONRAY).
| Breastfeeding | Iothalamate is excreted into breast milk in very small amounts (estimated M/P ratio <0.01). The exposure to the infant is negligible (less than 1% of maternal dose). No adverse effects have been reported. However, consider interrupting breastfeeding for 12-24 hours after contrast administration to minimize exposure further, especially in preterm or hypothyroid infants. |
| Teratogenic Risk | Iodinated contrast media, including iothalamate, cross the placenta. Fetal exposure may cause transient neonatal hypothyroidism, particularly if administered near term. No teratogenic effects have been documented in human studies; however, the theoretical risk of free iodide-induced fetal thyroid suppression exists. Use in pregnancy only if clearly needed, with careful risk-benefit assessment. First trimester exposure: no evidence of teratogenicity; second/third trimester: risk of neonatal hypothyroidism if high doses near delivery. |
■ FDA Black Box Warning
Risk of serious adverse reactions including fatal anaphylaxis, renal failure, and cardiovascular complications. Use with caution in patients with history of allergy, asthma, or renal impairment.
| Serious Effects |
Absolute: Known hypersensitivity to iodine-containing contrast media, anuria. Relative: Renal impairment, multiple myeloma, diabetes, dehydration, sickle cell disease.
| Precautions | Hypersensitivity reactions (anaphylaxis), renal toxicity (contrast-induced nephropathy), cardiovascular effects (arrhythmias, hypotension), extravasation risk, and thyroid dysfunction in predisposed patients. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function and hydration status before and after administration. Assess for signs of contrast-induced nephropathy. In pregnancy, monitor fetal heart rate if using high doses near term. For neonates exposed in utero near delivery, perform thyroid function tests (TSH, free T4) within the first week of life and at 2-3 weeks to detect transient hypothyroidism. |
| Fertility Effects | No specific studies on fertility effects. Iodinated contrast agents are not known to impair fertility or reproductive function in humans. No evidence of mutagenicity or clastogenicity in standard assays. |